Compare HQI & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HQI | LYEL |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | United States | United States |
| Employees | 75000 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.1M | 195.8M |
| IPO Year | 2008 | 2021 |
| Metric | HQI | LYEL |
|---|---|---|
| Price | $17.73 | $15.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $19.00 | ★ $37.88 |
| AVG Volume (30 Days) | 25.4K | ★ 145.2K |
| Earning Date | 11-12-2026 | 11-16-2026 |
| Dividend Yield | ★ 1.44% | N/A |
| EPS Growth | ★ 73.08 | N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $30,640,000.00 | $36,000.00 |
| Revenue This Year | $0.54 | N/A |
| Revenue Next Year | $5.47 | N/A |
| P/E Ratio | $53.68 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.38 | $7.20 |
| 52 Week High | $20.84 | $45.00 |
| Indicator | HQI | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 45.91 | 58.08 |
| Support Level | $15.28 | $7.20 |
| Resistance Level | $18.49 | $15.38 |
| Average True Range (ATR) | 0.98 | 0.78 |
| MACD | -0.09 | 0.36 |
| Stochastic Oscillator | 34.17 | 77.78 |
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.